Abstract
Purpose: To investigate the influence of vitamin K2 on bone mineral density, bone metabolism and serum tissue protease K (cathepsin K) in female patients with osteoporosis.Method: A total of 210 osteoporosis patients in Affiliated Hospital of Nanjing University of Chinese Medicine who met the inclusion criteria were selected from January 2017 to January 2018. The patients were randomly divided into vitamin K2 group, strontium renate group and blank control group (70 patients/group). Strontium ranelate group was orally given 2 g of strontium ranelate daily, while vitamin K2 group received 15 mg of Gulikang capsule 3 times a day. Bone mineral density (BMD) and serum osteocalcin (BGP), β-collagen degradation product (β-crosslaps), type I procollagen amino terminal propeptide (PINP), cathepsin K (cathe K) and TRAP were measured prior to drug treatment, and six months after surgery, using standard procedures.Results: Relative to the blank control, hip and lumbar spine density of vitamin K2 and strontium ranelate groups increased to varying degrees. Strontium ranelate group had significantly higher bone mineral density (BMD) than any other groups (p < 0.05), and also had the lowest osteoclast activity (β-crosslaps and TRAP) and the highest osteogenic activity (BGP and PINP). On the other hand, osteoclast and osteogenic activities increased significantly (p < 0.05) in the vitamin K2 group.Conclusion: Appropriate vitamin K2 treatment improves BMD in the hip and waist of women with osteoporosis by promoting osteogenic activity, and by reducing osteoclast activity and cathepsin K expression.Keywords: Osteoporosis, Bone mineral density, Strontium ranelate, Vitamin K2
Highlights
Post-menopausal osteoporosis (PMO) refers to changes in bone metabolism caused by decreased estrogen levels, resulting in increased loss of osteoclasts and trabecular bone
Relative to the blank control group, changes in bone metabolism and cathepsin K (cathe K) were more obvious in the vitamin K2 group and the strontium ranelate group than in control (p < 0.05)
Changes in bone metabolism in the patients given strontium ranelate group were more obvious than those in the vitamin K2 group, while changes in cathe K were markedly higher in vitamin K2 group than in the group that received strontium ranelate (p < 0.05)
Summary
Post-menopausal osteoporosis (PMO) refers to changes in bone metabolism caused by decreased estrogen levels, resulting in increased loss of osteoclasts and trabecular bone. It causes bone fragility and bone fractures. Osteoporosis is a frequently-occurring disease, and it is marked by decreased bone mass and altered bone structure, which lead to increased bone fragility and increased risk of bone fracture [2,3]. The antiosteoporosis drugs in use are agents that inhibit bone resorption and increase bone formation. They include parathyroid hormone [9] and bisphosphonates [10]. Vitamin K2 ameliorates imbalance in bone tissue metabolism through regulation of bone biogenesis and inhibition of the rate of bone resorption [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
